¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"secondary host"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
¿µ¹® secondary infection ÇÑ±Û ÀÌÂ÷°¨¿°
¼³¸í   
  ¾î¶² º´¿øÃ¼ÀÇ °¨¿°¿¡ ÀÇÇÏ¿© º»ÀÎÀÇ ÀúÇ×·ÂÀÌ ¾àÇØÁ³À» ¶§ ¸öÀÇ ´Ù¸¥ ºÎÀ§·Î ÀüÀÌÇÏ¿© ´Ù½Ã °¨¿°À» ÀÏÀ¸Å°´Â °Í. º´¿øÃ¼°¡ ÀÎü¿¡ Ä§ÀÔÇÏ¿© Æ¯Á¤ÇÑ ±â°üÀ̳ª Á¶Á÷¿¡¼­ º´¿øÃ¼°¡ Áõ½ÄÇϰí, ±×°÷¿¡ Æ¯À¯ÀÇ º´Å͸¦ ÀÏÀ¸Å°´Â °ÍÀÌ 1Â÷°¨¿° ¶Ç´Â Ãʰ¨¿°ÀÌ´Ù. ÀÌ 1Â÷°¨¿°ÀÇ º´ÅÍÀÇ º´¿øÃ¼°¡ Ç÷°ü-¸²ÇÁ°ü-±â°ü-¼ÒÈ­°ü-¿ä°ü µîÀÇ ±æÀ» µû¶ó °°Àº ±â°üÀÇ ´Ù¸¥ ºÎÀ§³ª ´Ù¸¥ ±â°üÀ¸·Î ¿î¹ÝµÇ¾î °¨¿°À» ÀÏÀ¸Å²´Ù. µû¶ó¼­ 1Â÷°¨¿°¿¡ ÀÇÇÏ¿© ÃæºÐÇÑ ¸é¿ªÀÌ µÉ °æ¿ì¿¡´Â 2Â÷°¨¿°ÀÌ ÀϾÁö ¾Ê´Â´Ù. ¿¹¸¦ µé¾î, À¯Ç༺ °¨±â¿¡ °É·ÈÀ» ¶§ ¼¼±Õ¿¡ ÀÇÇÑ Æó·ÅÀÌ µÚµû¸£´Â °æ¿ì¸¦ À̸¥´Ù. Æó·Å±Õ, È­³ó¾Ë±Õ, ´ëÀå±Õ µûÀ§°¡ ÀÖ´Ù. 
¿µ¹® host ÇÑ±Û ¼÷ÁÖ
¼³¸í   
  ´Ù¸¥ »ý¹°(±â»ýü)À» ±â»ý½ÃÄÑ, ¿µ¾çÀ» °ø±ÞÇϴ µ¿¹° ¶Ç´Â ½Ä¹°. ¸¶Áö¸·ÀÇ ¼öÁÖ¸¦ Á¾¼÷ÁÖ, ¹ßÀ°ÀÇ µµÁß¿¡ ±â»ýÇϴ ¼÷ÁÖ¸¦ Áß°£ ¼÷ÁÖ¶ó°í ÇÑ´Ù. ±â»ýµ¿¹° Áß¿¡´Â ¼÷ÁÖ°¡ Æ¯Á¤ÇÑ Á¾ÀÏ ¶§µµ ÀÖ°í ¶Ç ¸¹Àº ±â»ýÃæ°ú °°À̱נ¹ß»ý´Ü°è¿¡ µû¶ó ¸¹Àº Á¾·ùÀÇ ¼÷ÁÖ¸¦ ÇÊ¿ä·Î Çϴ °Íµµ ÀÖ´Ù. ÀÌ °æ¿ì ¾Ö¹ú·¹°¡ ±â»ýÇϴ ¼÷ÁÖ¸¦ Áß°£¼÷ÁÖ, ¼ºÃ¼°¡ ±â»ýÇϴ ¼÷ÁÖ¸¦ ÃÖÁ¾¼÷ÁÖ¶ó°í ÇÑ´Ù. °£ÁúÀΠ°æ¿ì¿¡´Â ¹°°íµ¿ÀÌ Áß°£¼÷ÁÖÀ̰í, ¼Ò-¾ç µîÀº ÃÖÁ¾¼÷ÁÖ°¡ µÈ´Ù. ±â»ý½Ä¹°¿¡´Â °Ü¿ì»ìÀ̿͠°°ÀÌ Á¹Âü³ª¹« µîÀ» ¼÷ÁַΠÇÏ¿© ½º½º·Î ±¤ÇÕ¼ºÀ» Çϸ鼭µµ ¼÷ÁÖ¿¡°Ô¼­ ¿µ¾çÀ» ¾ò´Â °Í°ú, ¾ß°í¿Í °°ÀÌ »ý°­ µîÀÇ »Ñ¸®¸¦ ¼÷ÁַΠÇÏ¿© ¼÷ÁÖ¿¡°Ô¼­¸¸ ¿µ¾çÀ» ÀÇÁ¸Çϴ °ÍÀÌ ÀÖ´Ù. ±â»ý»ý¹°¿¡´Â ÀÌ ¹Û¿¡µµ »ý¹°ÀÇ »çü³ª ±× ºÐÇØÁß¿¡ Àִ °Í, ¹èÃâ¹° µîÀ» ¼÷ÁַΠÇϴ °Íµµ ÀÖ´Ù.
¿µ¹® graft versus host reaction ÇÑ±Û ÀÌ½ÄÆí´ë ¼÷ÁÖ¹ÝÀÀ
¼³¸í   
  ¸é¿ªÀ̶õ ÀÚ½ÅÀÇ °Í°ú ÀÚ½ÅÀÇ °ÍÀÌ ¾Æ´Ñ °ÍÀ» ±¸ºÐÇØ¼­ ÀÚ½ÅÀÇ °ÍÀÌ ¾Æ´Ñ °ÍÀ» °ø°ÝÇÏ¿© »ý¹°ÇÐÀû È°¼ºÀ» ¾ø¾Ö°Å³ª Á¦°ÅÇϴ °ÍÀÌ´Ù. ÀÌ ¸é¿ªÀº ÁַΠÇ÷¾×¿¡ Àִ ¼¼Æ÷¿¡ ÀÇÇØ¼­ ÀÌ·ç¾îÁø´Ù. Æ¯È÷ ¸²ÇÁ±¸´Â ÀÌ ¸é¿ª¿¡ ÁßÃßÀûÀΠ¿ªÇÒÀ» Çϴ ¼¼Æ÷ÀÌ´Ù. ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀÀ̶ó´Â °ÍÀº À̽ĵǾî¿Â Á¶Á÷¿¡ Á¸ÀçÇϴ ŸÀÎÀÇ Ç÷±¸µéÀÌ ¼÷ÁÖÀÇ ¼¼Æ÷¸¦ °ø°ÝÇϴ °ÍÀ» ¸»ÇÑ´Ù. Áï À̽ĵǾî¿Â Á¶Á÷°ú ÇÔ²² µé¾î¿Â Ç÷±¸µéÀÌ À̽ÄÀ» ¹ÞÀº »ç¶÷ÀÇ ¼¼Æ÷¸¦ Å¸ÀÎÀÇ °ÍÀ¸·Î ÀÎÁöÇØ¼­ °ø°ÝÇϴ Çö»óÀÌ´Ù. À̰ÍÀº À̽ÄÀ» ¹ÞÀº »ç¶÷ÀÇ ¸é¿ª»óŰ¡ Á¤»óÀûÀÏ °æ¿ì¿¡´Â ÀϾÁö ¾Ê´Âµ¥ ¿Ö³ÄÇϸ頸鿪»óŰ¡ Á¤»óÀÏ °æ¿ì¿¡´Â À̽ĵǾî¿Â Àå±â¿Í ´õºÒ¾î µé¾î¿Â Å¸ÀÎÀÇ Ç÷±¸µéÀ» À̽ÄÀ» ¹ÞÀº »ç¶÷ÀÇ Ç÷±¸°¡ Å¸ÀÎÀÇ °ÍÀ¸·Î ÀÎÁöÇØ¼­ °ø°ÝÀ» ÇÏ°í ¼ýÀûÀ¸·Î À¯¸®ÇÏ¿© ¸ðµÎ Á×ÀÏ ¼ö°¡ Àֱ⠶§¹®ÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • accidental host
    ¿ì¿¬¼÷ÁÖ
  • definitive host
    Á¾¼÷ÁÖ
  • final host
    Á¾¼÷ÁÖ
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • host
    ¼÷ÁÖ
  • host adaptation
    ¼÷ÁÖÀûÀÀ
  • host attribute
    ¼÷ÁÖ¼Ó¼º
  • host defense
    ¼÷ÁÖ¹æ¾î
  • host integration factor
    ¼÷ÁÖÅëÇÕÀÎÀÚ
  • host preference
    ¼÷ÁÖ¼±È£
  • host range
    ¼÷ÁÖ¹üÀ§
  • host selection
    ¼÷ÁÖ¼±ÅÃ
  • host specificity
    ¼÷ÁÖÆ¯À̼º
  • host susceptibility
    ¼÷ÁÖ°¨¼ö¼º
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • host defense
    ¼÷ÁÖ¹æ¾î
  • host
    ¼÷ÁÖ
  • definitive host
    Á¾¼÷ÁÖ
  • intermediate host
    Áß°£¼÷ÁÖ
  • reservoir host
    º¸À¯¼÷ÁÖ
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ
  • secondary sexual character
    ÀÌÂ÷¼ºÂ¡
  • secondary wound closure
    ÀÌÂ÷»óóºÀÇÕ
  • secondary dentition
    (¢¡permanent tooth) °£´Ï, ¿µ±¸Ä¡¾Æ
  • secondary hemostasis
    ÀÌÂ÷ÁöÇ÷
  • secondary infection
    ÀÌÂ÷°¨¿°
  • secondary nodule
    (¢¡germinal center) Á¾ÀÚÁß½É, ¹èÁß½É
  • secondary
    ÀÌÂ÷-, Á¦ÀÌ-, ¼Ó¹ß-
  • secondary suture
    ÀÌÂ÷ºÀÇÕ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • secondary amenorrhea
    ÀÌÂ÷¹«¿ù°æ, ¼Ó¹ß¹«¿ù°æ
  • secondary aqueous
    Àç»ý¹æ¼ö, ÀÌÂ÷¹æ¼ö
  • secondary cardiomyopathy
    ÀÌÂ÷½ÉÀå±ÙÀ°º´Áõ
  • secondary constriction
    ÀÌÂ÷ÇùÂø
  • secondary contact
    ÀÌÂ÷Á¢ÃË
  • secondary culture
    µÎ¹øÂ°½É±â
  • secondary biliary cirrhosis
    ¼Ó¹ß¾µ°³°ü°£°æÈ­(Áõ)
  • secondary dentition
    (¢¡permanent tooth) °£´Ï, ¿µ±¸Ä¡¾Æ
  • secondary disease
    ¼Ó¹ßº´
  • secondary dysmenorrhea
    ÀÌÂ÷¿ù°æÅë
  • secondary ending
    ÀÌÂ÷Á¾¸»
  • secondary gout
    ÀÌÂ÷Åëdz
  • secondary hemorrhage
    ¼Ó¹ßÃâÇ÷, ÀÌÂ÷ÃâÇ÷
  • secondary hypertension
    ÀÌÂ÷°íÇ÷¾Ð
  • secondary hypogonadism
    ¼Ó¹ß»ý½Ä»ùÀúÇÏÁõ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • haploid secondary gametocyte
    Ȭ¹è¼öüÀÌÂ÷»ý½Ä¼¼Æ÷
  • immune response, secondary
    ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • immunodeficiency syndrome, secondary
    ÀÌÂ÷¼º ¸é¿ª°áÇÌ ÁõÈıº, ¼Ó¹ß¼º ¸é¿ª°áÇÌ ÁõÈıº
  • infection, secondary
    ÀÌÂ÷°¨¿°
  • process, secondary (psychic)
    ÀÌÂ÷°úÁ¤.
  • graft versus host disease
    ´ë¼÷ÁÖÀÌ½ÄÆíÁúȯ
  • graft versus host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´.
  • graft versus host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ(ì¹ãÕø¸ÓßâÖñ«Úãëë).
  • graft versus host reaction (GVHR)
    ´ë¼÷ÁÖÀÌ½ÄÆí¹ÝÀÀ
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë ¼÷ÁÖº´
  • host
    ¼÷ÁÖ
  • host
    ¼÷ÁÖ
  • host adaptation
    ¼÷ÁÖÀûÀÀ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • secondary yolk sac [secondary vitelline sac]
    ÀÌÂ÷³­È²ÁÖ¸Ó´Ï
  • compromised host
    ÀúÇ×·Â ÀúÇϼ÷ÁÖ
  • definitive host =final h.
    ÃÖÁ¾¼÷ÁÖ(¡­âÖñ«).
  • final host
    ÃÖÁ¾¼÷ÁÖ, Á¾¼÷ÁÖ
  • graft versus host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • graft versus host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´.
  • graft versus host disease
    ´ë¼÷ÁÖÀÌ½ÄÆíÁúȯ
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ(ì¹ãÕø¸ÓßâÖñ«Úãëë).
  • graft versus host reaction (GVHR)
    ´ë¼÷ÁÖÀÌ½ÄÆí¹ÝÀÀ
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë ¼÷ÁÖº´
  • host
    ¼÷ÁÖ
  • host
    ¼÷ÁÖ
  • host adaptation
    ¼÷ÁÖÀûÀÀ.
  • host attribute
    ¼÷ÁÖ¼Ó¼º.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Host
    ¼÷ÁÖ
    [¿¾ ¿ë¾î] ¼÷ÁÖ
  • Secondary yolk sac [Secondary vitelline sac]
    ÀÌÂ÷³­È²ÁÖ¸Ó´Ï
    [¿¾ ¿ë¾î] ÀÌÂ÷³­È²³¶
  • Secondary segmental bronchus
    ±¸¿ª±â°üÁö°¡Áö
    [¿¾ ¿ë¾î] ÀÌÂ÷±¸±â°üÁö
  • Secondary tympanic membrane
    µÑ°°í¸·
    [¿¾ ¿ë¾î] Á¦ÀÌ°í¸·
  • Secondary spiral lamina
    µÑ°³ª¼±ÆÇ
    [¿¾ ¿ë¾î] Á¦2³ª¼±ÆÇ
  • Secondary fissure
    µÑ°ƴ»õ
    [¿¾ ¿ë¾î] Á¦2¿­
  • Secondary polar body
    ÀÌÂ÷±ØÃ¼
    [¿¾ ¿ë¾î] ÀÌÂ÷±ØÃ¼
  • Secondary oocyte
    ÀÌÂ÷³­¸ð¼¼Æ÷
    [¿¾ ¿ë¾î] ÀÌÂ÷³­¸ð¼¼Æ÷
  • Secondary oocyte, Metaphase II
    ÀÌÂ÷³­¸ð¼¼Æ÷, ÀÌÂ÷°¨¼öºÐ¿­Áß±â
    [¿¾ ¿ë¾î] Á¦À̳­¸ð¼¼Æ÷,ÀÌÂ÷Áß±â
  • Secondary follicle
    ÀÌÂ÷³­Æ÷
    [¿¾ ¿ë¾î] ÀÌÂ÷³­Æ÷
  • Secondary ovarian follicle
    ÀÌÂ÷³­Æ÷
    [¿¾ ¿ë¾î] ÀÌÂ÷³­Æ÷
  • Secondary visceral nucleus
    ÀÌÂ÷³»Àå½Å°æÇÙ
    [¿¾ ¿ë¾î] Á¦2Àå½Å°æÇÙ
  • Secondary abdominal implantation
    ÀÌÂ÷¹è¾ÈÂø»ó
    [¿¾ ¿ë¾î] ÀÌÂ÷Àûº¹ºÎÂø»ó
  • Secondary bone
    ÀÌÂ÷»À
    [¿¾ ¿ë¾î] ÀÌÂ÷°ñ
  • Secondary osteon
    ÀÌÂ÷»À´ÜÀ§
    [¿¾ ¿ë¾î] ÀÌÂ÷°ñ¿ø
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • secondary amebic meningoencephalitis
    ÀÌÂ÷¾Æ¸Þ¹Ù¼ö¸·³ú¿°
  • secondary echinococcosis
    ÀÌÂ÷Æ÷ÃæÁõ
  • secondary infection
    ÀÌÂ÷°¨¿°
  • accidental host
    ¿ì¿¬¼÷ÁÖ
  • alternate host
    ±³´ë¼÷ÁÖ
  • amplifier host
    ÁõÆø¼÷ÁÖ
  • crustacean host
    °©°¢·ù¼÷ÁÖ
  • definitive host
    Á¾¼÷ÁÖ
  • first intermediate host
    Á¦ÀÏÁß°£¼÷ÁÖ
  • host
    ¼÷ÁÖ
  • host parasite relationship
    ¼÷ÁÖ±â»ýÃæ°ü°è
  • host preference
    ¼÷ÁÖ¼±È£
  • host range
    ¼÷ÁÖ¹üÀ§
  • host selection
    ¼÷ÁÖ¼±ÅÃ
  • host specificity
    ¼÷ÁÖÆ¯À̼º
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cloning host
    Ŭ·Î´× ¼÷ÁÖ(âÖñ«)
  • host
    ¼÷ÁÖ(âÖñ«)
  • host-cell reactivation
    ¼÷ÁÖ ¼¼Æ÷ ÀçȰ¼ºÈ­(âÖñ«á¬øàî¢üÀàõûù)
  • host-controlled modification
    ¼÷ÁÖÁ¦¾î ¼ö½Ä(âÖñ«ð¤åÙáóãÞ)
  • host-controlled restriction
    ¼÷ÁÖÁ¦¾î Á¦ÇÑ(âÖñ«ð¤åÙð¤ùÚ)
  • host-guest system
    ÁÖ-°´(ñ«-ËÔ) ½Ã½ºÅÛ
  • host-induced modification
    ¼÷ÁÖÀ¯µµ ¼ö½Ä(âÖñ«ë¯ÓôáóãÞ)
  • host range
    ¼÷ÁÖ ¹üÀ§(âÖñ«ÛôêÌ)
  • host-range mutant
    ¼÷ÁÖ¹üÀ§ º¯ÀÌÁÖ(âÖñ«ÛôêÌܨì¶ñ»)
  • integration host factor
    ÅëÇÕ ¼÷ÁÖÀÎÀÚ(÷ÖùêâÖñ«ì×í­)
  • secondary acidosis
    ÀÌÂ÷ »êÁõ(ì£ó­ß«ñø)
  • secondary active transport
    ÀÌÂ÷ ´Éµ¿¼ö¼Û(ì£ó­ÒöÔÑâÃáê)
  • secondary alkalosis
    ÀÌÂ÷(ì£ó­) ¾ËÄ®¸®Áõ(ñø)
  • secondary bile acid
    ÀÌÂ÷ ´ãÁó»ê(ì£ó­ÓÅñðß«)
  • secondary bond
    ÀÌÂ÷ °áÇÕ(ì£ó­Ì¿ùê)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • host
    ¼÷ÁÖ, ¼ö¿ëÀÚ, ÇÇÀ̽Äü
  • host computer
    ÁÖÄÄÇ»ÅÍ
  • secondary
    ÀÌÂ÷(¼º)ÀÇ, ¼Ó¹ß(¼º)ÀÇ
  • secondary anemia
    ¼Ó¹ß¼ººóÇ÷
  • secondary infection
    ÀÌÂ÷°¨¿°, ¼Ó¹ß°¨¿°
  • secondary lesion
    ÀÌÂ÷¼ºº´º¯, ÀÌÂ÷¹ßÁø, ¼Ó¹ßÁø
  • secondary ossification center
    ÀÌÂ÷°ñÈ­Áß½É
  • secondary pneumonia
    ¼Ó¹ß¼ºÆó·Å
  • secondary sex characteristic
    ÀÌÂ÷¼ºÂ¡
  • secondary sterility
    ¼Ó¹ßºÒÀÓ
  • secondary tuberculosis
    ÀÌÂ÷¼º°áÇÙ
  • secondary X-ray
    ÀÌÂ÷X¼±
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
SA salicylic acid; saline [solution]; salt added; sarcoidosis; sarcoma; scalenus anticus; secondary ame...
GVHD Graft-Versus-Host Disease; ½Ä´ëÁÖ Áúȯ
GVH, GvH graft-versus-host
GVHD, GvHD graft-versus-host disease
GVHR, GvHR graft-versus-host reaction
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
LSIMS Liquid secondary ion mass spectrometry
S Secondary
SIMS Secondary Ion Mass Spectrometry
SLC Secondary Lymphoid-tissue Chemokine
SP Secondary Polycythaemia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • host
    ¼÷ÁÖ, °³Ã¼, ¼ö¿ëÀÚ, ÇÇÀ̽Äü
    1. ¼÷ÁÖ-´Ù¸¥ »ý¹°À» ±â»ý½ÃÄÑ, ¿µ¾çÀ» °ø±ÞÇÏ´Â µ¿¹° ¶Ç´Â ½Ä¹°. 2. ÇÇÀ̽Äü, ¼ö¿ëÀÚ-´Ù¸¥ »ý¹°·ÎºÎÅÍ ±â°ü ¶Ç´Â Á¶Á÷ÀÇ À̽ÄÀ» ¹Þ´Â ¼ö¿ëÀÚ.
  • host-parasitite relationship
    ¼÷ÁÖ-±â»ýüÀÇ »óÈ£ °ü°è
  • pneumonia,in immunocompromised host
    ¸é¿ª ±â´É ÀúÇÏ ¼÷ÁÖÀÇ
  • brain vesicle`s secondary
    ÀÌÂ÷ ³úÆ÷
    Èı⠹èÅ ºÐÈ­·Î Çü¼ºµÇ´Â ³× °³ÀÇ ³ú³¶À¸·Î¼­ Àü³ú·ÎºÎÅÍ ºÐÈ­µÇ´Â Á¾³ú¿Í °£³ú, ´É³ú·ÎºÎÅÍ ºÐÈ­µÇ´Â Èijú¿Í ¼ö³ú¸¦ Æ÷ÇÔÇÑ´Ù.
  • secondary activation
    ÀÌÂ÷Àû Ȱ¼º
  • secondary amine
    ÀÌÂ÷ ¾Æ¹Î
  • secondary anemia
    ¼Ó¹ß¼º ºóÇ÷
  • secondary bond
    ÀÌÂ÷ °áÇÕ
    ÀϹÝÀûÀ¸·Î ¼ö¼Ò °áÇÕ, ¹Ýµ¥¸£¹ß½º Èû µîÀ» ¸»ÇÏ¸ç °áÇÕ·ÂÀº ÀÏÂ÷ °áÇշ¿¡ ºñÇÏ¸é ¸Å¿ì ÀÛ´Ù
  • secondary caries
    ÀÌÂ÷ ¿ì½Ä
    ½ÉºÎ¿¡ ¹ÌÄ£ ¹ý¶ûÁú ¿ì½ÄÀÌ »ó¾ÆÁú °æ°è¸¦ ¿·À¸·Î ÆÛÁ®¼­ °Å²Ù·Î Ç¥¸éÂÊÀ¸·Î ÁøÇàÇÏ´Â ¿ì½Ä. ¿ì½ÄÀ» ÃæÀüÇÑ ÈÄ ±× º¯¿¬¿¡¼­ ´Ù½Ã ÀϾ´Â ¿ì½Ä.
  • secondary cementum
    ÀÌÂ÷ ¹é¾ÇÁú, Á¦2¹é¾ÇÁú
    ÀÏÂ÷ ¹é¾ÇÁú ÀÌÈÄ¿¡ Çü¼ºµÈ ¸ðµç ÃþÀ» °¡¸®Å°´Â ¿ë¾î. ¼¼Æ÷¼º ȤÀº ºñ¼¼Æ÷¼ºÀÌ´Ù.
  • secondary crown
    ¿Ü°ü
  • secondary dentin formation
    ÀÌÂ÷ »ó¾ÆÁú Çü¼º
    Åë»óÀûÀÎ ±â´ÉÀû ±×¸®°í ¿­ ÀûÀÎ Àڱؿ¡ ´ëÇÑ Á¡Â÷ÀûÀÎ Ãß°¡Àû »ó¾ÆÁú Çü¼ºÀÌ¸ç ¹æ»ç¼± »çÁø »óÀ¸·Î Ä¡°üºÎ »ó¾ÆÁú µÎ²²ÀÇ ±ÕÀÏÇÑ Áõ°¡ ¾ç»óÀ» º¸À̰í ÀÖ´Ù. ´ëºÎºÐÀÇ ¼ºÀο¡´Â ÀÌ·¯ÇÑ °úÁ¤ÀÌ Á¸ÀçÇϸç ÀÌÀÇ Á¤µµ´Â °³Àο¡ µû¶ó ´Ù¾çÇÏ´Ù. 2Â÷ »ó¾ÆÁúÀº Ä¡¾Æ Ç¥¸é¿¡¼­ Ä¡¼ö±îÁö ¿ì½Ä º´º¯ÀÌ ÁøÇàµÇ´Âµ¥ °É¸®´Â ½Ã°£°ú °Å¸®¸¦ Áõ°¡½ÃŰ°Ô µÈ´Ù. ¶ÇÇÑ Ä¡¼ö°¢°ú °°Àº Ç¥ÃþÀÇ Ä¡¼ö Á¶Á÷À» ¸ÍÃâ ÈÄ ¼ö³â À̳»¿¡ 2Â÷ »ó¾ÆÁú·Î ´ëÄ¡½ÃÅ´À¸·Î½á ¼öº¹ ½Ã¼ú ½Ã ±â°èÀûÀÎ Ä¡¼ö ³ëÃâ °¡´É¼ºÀ» °¨¼Ò½ÃŲ´Ù. ÇÑÆí Àڱؿ¡ ´ëÇÑ Ä¡¼öÀÇ ¹Î°¨¼ºÀ» °¨¼Ò½Ã۱⠶§¹®¿¡ Ä¡¼ö °Ë»ç¿Í Ä¡¾Æ ÁúȯÀÇ Áø´Ü ½Ã À̰ÍÀÌ °í·ÁµÇ¾î¾ß ÇÑ´Ù.
  • secondary diagnosis
    ÀÌÂ÷ Áø´Ü
  • secondary disorder
    ÀÌÂ÷ Àå¾Ö
  • secondary efflorescence
    ¼Ó¹ß¼º ¹ßÁø
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
secondary host <epidemiology> See vector.
(05 Dec 1998)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
accidental host One that harbors an organism which usually does not infect it.
(05 Mar 2000)
amplifier host A host in which infectious agents multiply rapidly to high levels, providing an important source of infection for vectors in vector-borne diseases.
(05 Mar 2000)
parasite-host ecosystem Complex of all parasite species and individuals associated with a specific host.
Synonym: parasite-host ecosystem.
Origin: parasite + G. Koinos, common, together
(05 Mar 2000)
paratenic host An intermediate host in which no development of the parasite occurs, although its presence may be required as an essential link in the completion of the parasite's life cycle; e.g., the successive fish host's that carry the plerocercoid of Diphyllobothrium latum, the broad fish tapeworm, to larger food fish eventually eaten by man or other final host's.
Synonym: transport host.
(05 Mar 2000)
reservoir host The host of an infection in which the infectious agent multiplies and/or develops, and upon which the agent is dependent for survival in nature; the host essential for the maintenance of the infection during times when active transmission is not occurring.
(05 Mar 2000)
graft-versus-host disease <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
graft-versus-host reaction <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
graft-versus-host response <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
cutaneous graft versus host reaction An acute erythematous maculopapular reaction with bulla formation in the most severe cases; chronic changes may resemble lichen planus or scleroderma.
(05 Mar 2000)
host An organism that is infected with or is fed upon by a parasitic or pathogenic organism (for example, a virus, nematode, fungus). The term can also be applied, loosely, to a plant supporting an epiphyte.
(09 Oct 1997)
host cell A cell which has been infected by a virus is known as the host cell of that virus.
A cell which is used in lab techniques such as DNA cloning to receive, maintain, and allow the reproduction of recombinant DNA cloning vectors. The DNA introduced with the vector is replicated whenever the cell divides and the recombinant proteins encoded for by the plasmid are reproduced in large quantities.
(13 Nov 1997)
host-parasite relations The interactions between two organisms, one of which lives at the expense of the other.
(12 Dec 1998)
host range The range of host species or cell types which a particular virus, bacteria, or parasite is able to infect or parasitise.
(09 Oct 1997)
host range mutant A mutant of phage or animal virus that grows normally in one of its host cells, but has lost the ability to grow in cells of a second host type.
(18 Nov 1997)
host restriction-modification A bacterial system where the bacterium is able to destroy invading DNA from a bacteriophage (virus which infects bacteria) while at the same time preventing the destruction of their own DNA. The phage DNA is cleaved by a restriction enzyme made by the bacterium, the bacterial DNA is modified (usually with methylation) so that the enzyme will not destroy it.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • a host of
    -ÀÌ ¸¹Àº
  • host
    ÁÖÀÎ; ±ºÁß; ¹«¸®
  • secondary
    Á¦ 2ÀÇ
  • definitive host
    (»ý)Á¾°á(°íÀ¯)¼÷ÁÖ
  • host
    (¼Õ´Ô¿¡ ´ëÇÏ¿©) ÁÖÀÎ;(¿©°üÀÇ) (³²ÀÚ) ÁÖÀÎ;(±â»ý »ý¹°ÀÇ) ¼÷ÁÖ;reckon(count) without one's ~ Á¦¸Ú´ë·Î Ä¡ºÎ(ÆÇ´Ü)ÇÏ´Ù
  • host
    ¸¹Àº ¶¼;´Ù¼ö;±º¼¼;heavenly ~s;~(s) of heaven ÇÏ´ÃÀÇ º°;õ»çÀÇ ¶¼
  • host city
    (°æ±â µîÀÇ)°³ÃÖ µµ½Ã
  • host computer
    (´Ü¸»±â,¸¶ÀÌÅ©·Î ÄÄÇ»Å͸¦ °Å´À¸°)È£½ºÆ® ÄÄÇ»ÅÍ;´ë¿ë·® ÄÄÇ»ÅÍ
  • host plant
    ±âÁÖ ½Ä¹°
  • intermediate host
    Áß°£¼÷ÁÖ(±â»ýÃæÀÇ À¯»ý±âÀÇ ¼÷ÁÖ)
  • post secondary education
    Áßµî °úÁ¤ ÈÄÀÇ ±³À°
  • secondary
    µÑ°ÀÇ;ÁßµîÀÇ;º¸Á¶ÀÚ;´ë¸®ÀÚ
  • secondary accent
    Á¦ 2¾×¼¾Æ®
  • secondary ballot
    °á¼± ÅõÇ¥
  • secondary base
    2·ç
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á